Quality of life as an endpoint in Phase I oncology clinical trials of novel chemotherapy drugs

References

• Wiklund I. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam. Clin. Pharmacol. 18(3), 351–363 (2004).
   PubMed Web of Science ®Google Scholar
• Fairclough DL. Patient reported outcomes as end points in medical research. Stat. Methods Med. Res. 13(2), 115–138 (2004).
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85, 365–376 (1993).
   PubMed Web of Science ®Google Scholar
• Cella DF, Tulsky DS, Gray G et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J. Clin. Oncol. 11(3), 570–579 (1993).
   PubMed Web of Science ®Google Scholar
• Murray KJ, Nelson DF, Scott C et al. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83–02. Int. J. Radiat. Oncol. Biol. Phys. 31(3), 453–459 (1995).
   PubMed Web of Science ®Google Scholar
• O’Boyle CA, Browne J, Hickey A, McGee HM, Joyce CRB. Schedule for the Evaluation of Individual Quality of Life (SEIQoL): A Direct Weighting Procedure for Quality of Life Domains (SEIQoL-DW): Administration Manual. Department of Psychology, Royal College of Surgeons, Dublin, Ireland (1995).
   Google Scholar
• O’Boyle CA, McGee HM, Hickey A et al. The Sschedule for the Evaluation of Individual Quality of Life (SEIQoL): Administration Manual. Royal College of Surgeons, Dublin, Ireland (1993).
   Google Scholar
• Broadhead JK, Robinson JW, Atkinson MJ. A new quality of life measure for oncology: The SEIQoL. J. Psychosoc. Onc. 16(1), 21–35 (1998).
   Web of Science ®Google Scholar
• Waldron D, O’Boyle CA, Kearney M, Moriarty M, Carney D. Quality of life measurement in advanced cancer: assessing the individual. J. Clin. Oncol. 17(11), 3603–3611 (1999).
   PubMed Web of Science ®Google Scholar
• Campbell S, Whyte F. The quality of life of cancer patients participating in Phase I clinical trials using SEIQoL-DW. J. Adv. Nurs. 30(2), 335–343 (1999).
   PubMed Web of Science ®Google Scholar
• Meropol NJ, Weinfurt KP, Burnett CB et al. Perceptions of patients and physicians regarding Phase I cancer clinical trials: implications for physician-patient communication. J. Clin. Oncol. 21(13), 2589–2596 (2003).
   PubMed Web of Science ®Google Scholar
• Cheng JD, Hitt J, Koczwara B et al. Impact of quality of life on patient expectations regarding Phase I clinical trials. J. Clin. Oncol. 18(2), 421–428 (2000).
   PubMed Web of Science ®Google Scholar
• Schutta KM, Burnett CB. Factors that influence a patient’s decision to participate in a Phase I cancer clinical trial. J. Adv. Nurs. 27(9), 1435–1438 (2000).
   Google Scholar
• Carlson LE, Bultz BD, Morris DG. Individualized quality of life, standardized quality of life, and distress in patients undergoing a Phase I trial of the novel therapeutic Reolysin (reovirus). Health Qual. Life Outcomes 3(1), 7 (2005).
   PubMedGoogle Scholar
• Daugherty C, Ratain MJ, Grochowski E et al. Perceptions of cancer patients and their physicians involved in Phase I trials. J. Clin. Oncol. 13(5), 1062–1072 (1995).
   PubMed Web of Science ®Google Scholar
• Nurgat ZA, Craig W, Campbell NC, Bissett JD, Cassidy J, Nicolson MC. Patient motivations surrounding participation in Phase I and Phase II clinical trials of cancer chemotherapy. Br. J. Cancer 92(6), 1001–1005 (2005).
   PubMed Web of Science ®Google Scholar
• Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363(9405), 263–270 (2004).
   PubMed Web of Science ®Google Scholar
• Roberts TG Jr, Goulart BH, Squitieri L et al. Trends in the risks and benefits to patients with cancer participating in Phase 1 clinical trials. JAMA 292(17), 2130–2140 (2004).
   PubMed Web of Science ®Google Scholar
• Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN. Design and results of Phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J. Clin. Oncol. 14(1), 287–295 (1996).
   PubMed Web of Science ®Google Scholar
• Horstmann E, McCabe MS, Grochow L et al. Risks and benefits of Phase 1 oncology trials, 1991 through 2002. N. Engl. J. Med. 352(9), 895–904 (2005).
   PubMed Web of Science ®Google Scholar
• Daugherty CK. Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J. Clin. Oncol. 17(5), 1601–1617 (1999).
   PubMed Web of Science ®Google Scholar
• Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 283(20), 2701–2711 (2000).
   PubMed Web of Science ®Google Scholar
• Miller M. Phase I cancer trials. A collusion of misunderstanding. Hastings Cent. Rep. 30(4), 34–43 (2000).
   PubMed Web of Science ®Google Scholar
• Kiebert GM, Curran D, Aaronson NK. Quality of life as an end point in EORTC clinical trials. European Organization for Research and Treatment for Cancer. Stat. Med. 17(5–7), 561–569 (1998).
   PubMed Web of Science ®Google Scholar
• Cox K. Enhancing cancer clinical trial management: recommendations from a qualitative study of trial participants’ experiences. PsychoOncology 9(4), 314–322 (2000).
   PubMed Web of Science ®Google Scholar
• Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-oncol. 5(2), 89–95 (2003).
   PubMed Web of Science ®Google Scholar
• Meyer F, Lueck A, Hribaschek A, Lippert H, Ridwelski K. Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma. Chemotherapy 50(6), 289–296 (2004).
   PubMed Web of Science ®Google Scholar
• Garufi C, Dogliotti L, D’Attino RM et al. Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a Phase I study. Cancer 91(4), 712–720 (2001).
   PubMed Web of Science ®Google Scholar
• Herman JM, Smith DC, Montie J et al. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology 64(1), 69–73 (2004).
   PubMed Web of Science ®Google Scholar
• Berdel WE, Knopf H, Fromm M et al. Influence of Phase I early clinical trials on the quality of life of cancer patients. A pilot study. Anticancer Res. 8(3), 313–321 (1988).
   PubMed Web of Science ®Google Scholar
• Cox K. Assessing the quality of life of patients in Phase I and II anticancer drug trials: interviews versus questionnaires. Soc. Sci. Med. 56(5), 921–934 (2003).
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Herbst RS, Rischin D et al. Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res. 9(6), 2040–2048 (2003).
   PubMed Web of Science ®Google Scholar
• Melink TJ, Clark GM, Von Hoff DD. The impact of Phase I clinical trials on the quality of life of patients with cancer. Anticancer Drugs 3(6), 571–576 (1992).
   PubMed Web of Science ®Google Scholar
• Rigg A, Cunningham D, Gore M et al. A Phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. Br. J. Cancer 75(1), 101–105 (1997).
   PubMed Web of Science ®Google Scholar
• Sherliker L, Steptoe A. Coping with new treatments for cancer: a feasibility study of daily diary measures. Patient Educ. Couns. 40(1), 11–19 (2000).
   PubMed Web of Science ®Google Scholar
• Moinpour CM, Sawyers TJ, McKnight B et al. Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. PsychoOncology 9(4), 340–354 (2000).
   PubMed Web of Science ®Google Scholar
• Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 16, 301–308 (2005).
   Google Scholar
• Trask PC. Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy. Health Qual. Life Outcomes 2, 37 (2004).
   PubMedGoogle Scholar
• McKenna SP, Doward LC. Integrating patient-reported outcomes. Value Health 7(Suppl. 1), S9–S12 (2004).
   Web of Science ®Google Scholar
• Cella DF, Tulsky DS. Measuring quality of life today: methodological aspects. Oncology (Williston Park) 4(5), 29–38 (1990).
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M. An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561–571 (1961).
   PubMed Web of Science ®Google Scholar
• Derogatis LR. Brief Symptom Inventory 18: Administration, Scoring and Procedures Manual. NCS Pearson Inc., MN, USA (2001).
   Google Scholar
• Derogatis LR, Melisaratos N. The brief symptom inventory: an introductory report. Psychol Med. 13, 595–605 (1983).
   PubMed Web of Science ®Google Scholar
• Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl. Psychol. Meas.1, 385–401 (1977).
   Web of Science ®Google Scholar
• Goldberg D. Manual of the General Hospital Questionnaire. NFER Publishing, Winsdor, UK (1978).
   Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67, 361–370 (1983).
   PubMed Web of Science ®Google Scholar
• McNair DM, Lorr M, Droppleman LF. EDITS Manual for the Profile of Mood States. Educational and Industrial Testing Service, CA, USA (1971).
   Google Scholar
• de Haes JC, van Kippenberg FC, Neijt JP. Measuring psychological and physical symptom distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br. J. Cancer 62, 1034–1038 (1990).
   PubMed Web of Science ®Google Scholar
• Stewart AL, Hays RD, Ware JE. The MOS short form general health survey. Med. Care 7, 724 (1988).
   Google Scholar
• Bergner M, Bobbitt RA, Pollard WE. Sickness impact profile: validation of a health status measure. Med. Care 14, 57–61 (1976).
   PubMed Web of Science ®Google Scholar